Cynthia Pussinen, CEO and Director of Estrella Immunopharma, Inc., filed an initial statement of beneficial ownership on November 3, 2026, reporting no securities held as of the triggering event date of October 25, 2026.

Key Highlights

  • Reporting person: Cynthia Pussinen, identified in the filing as CEO and Director of Estrella Immunopharma, Inc.
  • Event date: The date of the event requiring the statement is listed as October 25, 2026.
  • No securities owned: The filing states, "No securities in ESLA of any kind are beneficially owned."
  • No non-derivative holdings: Table I, covering non-derivative securities, contains no entries.
  • No derivative holdings: Table II, covering derivative securities such as options and warrants, also contains no entries.
  • Issuer: Estrella Immunopharma, Inc., trading on NASDAQ:ESLA, is identified as the issuer.

Pussinen Reports No Beneficial Ownership Upon Joining Estrella Immunopharma

According to the filing, Cynthia Pussinen submitted a Form 3 Initial Statement of Beneficial Ownership of Securities with the U.S. Securities and Exchange Commission on November 3, 2026. The statement was triggered by an event dated October 25, 2026, which the filing identifies as the date requiring the statement. Pussinen is listed as both a Director and an Officer with the title of CEO of Estrella Immunopharma, Inc. (NASDAQ:ESLA), headquartered at 5858 Horton St, Suite 370, Emeryville, California 94608.

The filing discloses that Pussinen holds no beneficial ownership of any securities issued by Estrella Immunopharma. The remarks section of the form states explicitly: "No securities in ESLA of any kind are beneficially owned." Both Table I, which covers non-derivative securities, and Table II, which covers derivative securities including puts, calls, warrants, options, and convertible securities, are blank with no reported holdings of any class or type.

The form was filed by one reporting person and signed by Cynthia Pussinen on November 3, 2026. This is an initial filing, not an amendment, and no prior Form 3 on file is referenced.

What Was Disclosed

Cynthia Pussinen, CEO and Director of Estrella Immunopharma, Inc. (NASDAQ:ESLA), filed a Form 3 reporting zero beneficial ownership of any company securities, both non-derivative and derivative, as of the October 25, 2026 event date.